**Abstract**

**Objective:** While selective serotonin reuptake inhibitors (SSRIs) constitute first line therapy of depression and anxiety disorders, their mechanism of action remains to be elucidated. Hybrid PET/MR systems allow us to simultaneously probe the engagement of molecular targets and concomitant changes in brain activity following the application of psychopharmaceuticals. This study was aimed to establish imaging methods to be applied on clinical samples in the future.

**Methods:** 7 subjects underwent two measurements at the Biograph mMR scanner. \[^11^C\]DASB was applied as bolus plus constant infusion. After 60 minutes, double-blind infusion of 7.5mg citalopram or saline was performed and scanning was continued for 60 minutes, such that equilibrium was attained. An event-related emotion identification paradigm was performed before and after drug challenge. Serotonin transporter occupancy was calculated from binding potentials obtained using metabolite-corrected plasma activity at equilibrium and non-specific binding from cerebellum.

**Results:** Average serotonin transporter occupancy was 62% in the regions investigated (thalamus: 63±16%, amygdala: 61%±17%, midbrain: 54%±17%, putamen: 64±13%, nucleus caudatus: 67%±13%). Functional MRI revealed decreased activation in the right inferior frontal (rIFC, p~FWE-cluster~=0.02) and left middle temporal gyri (lMTG, p~FWE-cluster~=0.03) to negative faces following citalopram infusion (for p=0.001 uncorrected on peak level).

**Conclusions:** The newly implemented methods yielded serotonin transporter occupancy values in agreement with published data obtained using well validated procedures \[1\]. FMRI results are at odds with increased activity during an emotional paradigm in the lMTG following 10 days of SSRI treatment observed by our group \[2\]. Further, meta-analysis revealed lower activation to negative stimuli in the rIFC of depressed patients \[3\]. These preliminary results indicate that acute challenge with a subtherapeutic SSRI dose elicits brain activation changes distinct to those seen with prolonged treatment. It will be interesting to see what insights will arise from direct integration of molecular and functional imaging data in clinical populations.
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